The roles of inflammation and immune mechanisms in Alzheimer's disease

[1]  A. Najafi,et al.  Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-β pathology. , 2016, Brain : a journal of neurology.

[2]  C. Granziera,et al.  In Vivo Imaging of Human Neuroinflammation. , 2016, ACS chemical neuroscience.

[3]  K. Blennow,et al.  sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers , 2016, EMBO molecular medicine.

[4]  J. Molinuevo,et al.  CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD , 2016, Neurobiology of Aging.

[5]  Stephen F. Carter,et al.  Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer’s disease , 2016, Brain : a journal of neurology.

[6]  Kazuki Harada,et al.  Gliotransmitter Release from Astrocytes: Functional, Developmental, and Pathological Implications in the Brain , 2016, Front. Neurosci..

[7]  K. Blennow,et al.  Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease , 2016, Molecular Neurodegeneration.

[8]  L. Wilkins.  Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial , 2015, Neurology.

[9]  D. Rujescu,et al.  The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease , 2015, Alzheimer's & Dementia.

[10]  M. Guillot-Sestier,et al.  Innate Immunity Fights Alzheimer's Disease , 2015, Trends in Neurosciences.

[11]  B. Stevens,et al.  Microglia Function in Central Nervous System Development and Plasticity. , 2015, Cold Spring Harbor perspectives in biology.

[12]  Chengjie Xiong,et al.  Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. , 2015, JAMA neurology.

[13]  M. Tansey,et al.  Inflammation in nervous system disorders , 2015, Neuroscience.

[14]  M. Guillot-Sestier,et al.  The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive? , 2015, Brain Research.

[15]  Joel T Dudley,et al.  Mapping the effects of drugs on the immune system , 2015, Nature Biotechnology.

[16]  G. Réus,et al.  The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders , 2015, Neuroscience.

[17]  A. Palmeri,et al.  Rodent models for Alzheimer’s disease drug discovery , 2015, Expert opinion on drug discovery.

[18]  David Bartrés-Faz,et al.  Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease , 2015, Neurobiology of Aging.

[19]  Guixiang Xu,et al.  Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. , 2015, Brain : a journal of neurology.

[20]  Burkhard Becher,et al.  Immune attack: the role of inflammation in Alzheimer disease , 2015, Nature Reviews Neuroscience.

[21]  M. Lynch,et al.  T Cells—Protective or Pathogenic in Alzheimer’s Disease? , 2015, Journal of Neuroimmune Pharmacology.

[22]  Andrew N Hoofnagle,et al.  Arginine Deprivation and Immune Suppression in a Mouse Model of Alzheimer's Disease , 2015, The Journal of Neuroscience.

[23]  O. Garaschuk,et al.  Neuroinflammation in Alzheimer's disease , 2015, The Lancet Neurology.

[24]  H. Stefánsson,et al.  Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease , 2015, Nature Genetics.

[25]  S. Younkin,et al.  Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia. , 2015, Human molecular genetics.

[26]  R. Ransohoff,et al.  TREM2 deficiency eliminates TREM2+ inflammatory macrophages and ameliorates pathology in Alzheimer’s disease mouse models , 2015, The Journal of experimental medicine.

[27]  Charles C. White,et al.  A TREM1 variant alters the accumulation of Alzheimer‐related amyloid pathology , 2015, Annals of neurology.

[28]  Nathan D. Price,et al.  IL-10 Alters Immunoproteostasis in APP Mice, Increasing Plaque Burden and Worsening Cognitive Behavior , 2015, Neuron.

[29]  M. Guillot-Sestier,et al.  Il10 Deficiency Rebalances Innate Immunity to Mitigate Alzheimer-Like Pathology , 2015, Neuron.

[30]  R. Petersen,et al.  Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural‐derived blood exosomes of preclinical Alzheimer's disease , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  G. Taglialatela,et al.  NFκB-Activated Astroglial Release of Complement C3 Compromises Neuronal Morphology and Function Associated with Alzheimer’s Disease , 2015, Neuron.

[32]  M. Schwartz,et al.  Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: boosting autoimmunity to fight-off chronic neuroinflammation. , 2014, Journal of autoimmunity.

[33]  Steffen Jung,et al.  Opposing Effects of Membrane-Anchored CX3CL1 on Amyloid and Tau Pathologies via the p38 MAPK Pathway , 2014, The Journal of Neuroscience.

[34]  J. Molinuevo,et al.  TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis , 2014, Science Translational Medicine.

[35]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[36]  Daphne Koller,et al.  Polarization of the Effects of Autoimmune and Neurodegenerative Risk Alleles in Leukocytes , 2014, Science.

[37]  P. Sanberg,et al.  The innate and adaptive immunological aspects in neurodegenerative diseases , 2014, Journal of Neuroimmunology.

[38]  S. Hickman,et al.  TREM2 and the neuroimmunology of Alzheimer's disease. , 2014, Biochemical pharmacology.

[39]  Marco Prinz,et al.  Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease , 2014, Nature Reviews Neuroscience.

[40]  F. Schmitt,et al.  Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models , 2014, Front. Genet..

[41]  E. Schadt,et al.  Unifying immunology with informatics and multiscale biology , 2014, Nature Immunology.

[42]  Sid O'Bryant,et al.  Developing novel blood-based biomarkers for Alzheimer's disease , 2014, Alzheimer's & Dementia.

[43]  Magda Tsolaki,et al.  Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. , 2013, Journal of Alzheimer's disease : JAD.

[44]  Toshiro K. Ohsumi,et al.  The Microglial Sensome Revealed by Direct RNA Sequencing , 2013, Nature Neuroscience.

[45]  M. Franceschi,et al.  CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study. , 2013, Current Alzheimer research.

[46]  Manasi Malik,et al.  CD33 Alzheimer's Risk-Altering Polymorphism, CD33 Expression, and Exon 2 Splicing , 2013, The Journal of Neuroscience.

[47]  Francis J McMahon,et al.  In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. , 2013, Brain : a journal of neurology.

[48]  D. Wesson,et al.  Response to Comments on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” , 2013, Science.

[49]  Keith A. Johnson,et al.  CD33 Alzheimer’s disease locus: Altered monocyte function and amyloid biology , 2013, Nature Neuroscience.

[50]  Bradley T. Hyman,et al.  Alzheimer’s Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid Beta , 2013, Neuron.

[51]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[52]  Pasko Rakic,et al.  A Transgenic Alzheimer Rat with Plaques, Tau Pathology, Behavioral Impairment, Oligomeric Aβ, and Frank Neuronal Loss , 2013, The Journal of Neuroscience.

[53]  F. Schmitt,et al.  Neuroinflammatory phenotype in early Alzheimer's disease , 2013, Neurobiology of Aging.

[54]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[55]  Henrik Zetterberg,et al.  Plasma tau levels in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[56]  F. LaFerla,et al.  Sustained Interleukin-1β Overexpression Exacerbates Tau Pathology Despite Reduced Amyloid Burden in an Alzheimer's Mouse Model , 2013, The Journal of Neuroscience.

[57]  D. Morgan,et al.  Review: Experimental manipulations of microglia in mouse models of Alzheimer's pathology: activation reduces amyloid but hastens tau pathology , 2013, Neuropathology and applied neurobiology.

[58]  C. Holmes.  Review: Systemic inflammation and Alzheimer's disease , 2013, Neuropathology and applied neurobiology.

[59]  A. Hofman,et al.  Variant of TREM2 associated with the risk of Alzheimer's disease. , 2013, The New England journal of medicine.

[60]  York Winter,et al.  Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease–like pathology and cognitive decline , 2012, Nature Medicine.

[61]  Murray Grossman,et al.  Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease , 2012, Neurology.

[62]  Donald A. Wilson,et al.  ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models , 2012, Science.

[63]  N. Greig,et al.  Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases , 2011 .

[64]  G. Gowing,et al.  How to get from here to there: macrophage recruitment in Alzheimer's disease. , 2011, Current Alzheimer research.

[65]  Chengjie Xiong,et al.  YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease , 2010, Biological Psychiatry.

[66]  R. Ransohoff,et al.  CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. , 2010, The American journal of pathology.

[67]  Ania K. Majewska,et al.  Microglial Interactions with Synapses Are Modulated by Visual Experience , 2010, PLoS biology.

[68]  M. Nedergaard,et al.  Functions of astrocytes and their potential as therapeutic targets , 2010, Neurotherapeutics.

[69]  C. Colton,et al.  Assessing activation states in microglia. , 2010, CNS & neurological disorders drug targets.

[70]  D. Holtzman,et al.  ApoE Promotes the Proteolytic Degradation of Aβ , 2008, Neuron.

[71]  Jun Tan,et al.  Blocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology , 2008, Nature Medicine.

[72]  C. Geula,et al.  Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease , 2007, Nature Medicine.

[73]  S. Goodman,et al.  Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review , 2004, Neuroepidemiology.

[74]  H. Gendelman,et al.  Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[75]  G. Forloni,et al.  The Continuing Failure of Bexarotene in Alzheimer's Disease Mice. , 2015, Journal of Alzheimer's disease : JAD.

[76]  E. Lander,et al.  Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .

[77]  K. Shudo,et al.  Cooperative therapeutic action of retinoic acid receptor and retinoid x receptor agonists in a mouse model of Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[78]  Xi Chen,et al.  Peripheral administration of the selective inhibitor of soluble tumor necrosis factor (TNF) XPro®1595 attenuates nigral cell loss and glial activation in 6-OHDA hemiparkinsonian rats. , 2014, Journal of Parkinson's disease.

[79]  D. Galimberti,et al.  Gender effects on plasma PGRN levels in patients with Alzheimer's disease: a preliminary study. , 2013, Journal of Alzheimer's disease : JAD.

[80]  M. Franceschi,et al.  CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo-Controlled Study. , 2013, Current Alzheimer research.

[81]  M. Sporn,et al.  The Retinoids : biology, chemistry, and medicine , 1994 .

[82]  A. Alzheimer.  Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .